|Trial Phase||Phase 1|
The following criteria is a partial list of reasons why patients may or may not be eligible to participate in this clinical trial. Further evaluation with a medical professional will be required to determine full eligibility.
The following criteria is provided for health care professionals.
* Proteasome inhibitor moderate resistance: Less than or equal to stable disease with prior treatment with proteasome inhibitor containing regimen at moderate doses defined as carfilzomib 27+ mg/m²/wk, bortezomib 1.3+ mg/m²/wk subcutaneously (SQ) or IV, or ixazomib 3+ mg/wk PO
The following is a listing of trial locations that are open and accepting patients.